مقایسهٔ روشها
روشهای انتخابی خود را کنار هم مرور کنید؛ ردیفهای متفاوت برجسته شدهاند.
| امتیاز فعالیت بیماری ۲۸ مفصلی (DAS28)× | شاخص فعالیت بیماری در اسپوندیلیت آنکیلوزان حمام (BASDAI)× | |
|---|---|---|
| حوزه | روماتولوژی | روماتولوژی |
| خانواده | Process / pipeline | Process / pipeline |
| سال پیدایش≠ | 1995 | 1994 |
| پدیدآور≠ | Prevoo et al. | Garrett et al. |
| نوع≠ | Clinician-rated | Patient-reported outcome (PRO) |
| منبع بنیادین≠ | Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48. DOI ↗ | Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291. link ↗ |
| نامهای دیگر≠ | DAS28, DAS28-CRP, DAS28-ESR | BASDAI, BAS-DAI |
| مرتبط≠ | 3 | 4 |
| خلاصه≠ | The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden. | The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials. |
| ScholarGateمجموعهداده ↗ |
|
|